CN113195510A - 吡喃葡萄糖基衍生物的制备方法及其中间体 - Google Patents

吡喃葡萄糖基衍生物的制备方法及其中间体 Download PDF

Info

Publication number
CN113195510A
CN113195510A CN202080007079.4A CN202080007079A CN113195510A CN 113195510 A CN113195510 A CN 113195510A CN 202080007079 A CN202080007079 A CN 202080007079A CN 113195510 A CN113195510 A CN 113195510A
Authority
CN
China
Prior art keywords
formula
vii
compound shown
compound
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080007079.4A
Other languages
English (en)
Other versions
CN113195510B (zh
Inventor
顾峥
曲桐
伍武勇
黄伟明
张宗远
吴天云
桑梓福
张英俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yichang Hec Changjiang Pharmaceutical Co ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of CN113195510A publication Critical patent/CN113195510A/zh
Application granted granted Critical
Publication of CN113195510B publication Critical patent/CN113195510B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种作为钠依赖性葡萄糖转运蛋白(SGLT)抑制剂的吡喃葡萄糖基衍生物类化合物的制备方法及其重要中间体。本发明所提供的制备方法操作简单，所得产物光学纯度高，总收率高，后处理简便，纯化容易，过程安全可控，适于工业化生产。

Description

PCT国内申请，说明书已公开。

Claims (37)

  1. PCT国内申请，权利要求书已公开。
CN202080007079.4A 2019-01-08 2020-01-08 吡喃葡萄糖基衍生物的制备方法及其中间体 Active CN113195510B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019100149305 2019-01-08
CN201910014930 2019-01-08
PCT/CN2020/070860 WO2020143653A1 (zh) 2019-01-08 2020-01-08 吡喃葡萄糖基衍生物的制备方法及其中间体

Publications (2)

Publication Number Publication Date
CN113195510A true CN113195510A (zh) 2021-07-30
CN113195510B CN113195510B (zh) 2022-12-23

Family

ID=71520932

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080007079.4A Active CN113195510B (zh) 2019-01-08 2020-01-08 吡喃葡萄糖基衍生物的制备方法及其中间体

Country Status (2)

Country Link
CN (1) CN113195510B (zh)
WO (1) WO2020143653A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113912567A (zh) * 2020-07-08 2022-01-11 宜昌东阳光长江药业股份有限公司 吡喃葡萄糖基衍生物的制备方法及其中间体

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022161377A1 (en) * 2021-01-27 2022-08-04 Sunshine Lake Pharma Co., Ltd. A phamaceutical composition comprising a glucopyranosyl derivative
CN114831175A (zh) * 2022-05-17 2022-08-02 华中农业大学 一种柑橘保鲜用添加剂及应用
CN117430571A (zh) * 2022-07-15 2024-01-23 宜昌东阳光长江药业股份有限公司 一种制备吡喃葡萄糖基衍生物的关键中间体及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159151A1 (en) * 2013-03-14 2014-10-02 Msd International Gmbh Methods for preparing sglt2 inhibitors
CN106083943A (zh) * 2015-04-30 2016-11-09 广东东阳光药业有限公司 一种吡喃葡萄糖基衍生物及其制备方法和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159151A1 (en) * 2013-03-14 2014-10-02 Msd International Gmbh Methods for preparing sglt2 inhibitors
CN106083943A (zh) * 2015-04-30 2016-11-09 广东东阳光药业有限公司 一种吡喃葡萄糖基衍生物及其制备方法和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LÁSZLÓ KÜRTI 等: "《有机合成中命名反应的战略性应用》", 31 August 2007 *
PAUL BOWLES ET AL.: "Commercial Route Research and Development for SGLT2 Inhibitor Candidate Ertugliflozin", 《ORG. PROCESS RES.DEV.》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113912567A (zh) * 2020-07-08 2022-01-11 宜昌东阳光长江药业股份有限公司 吡喃葡萄糖基衍生物的制备方法及其中间体
CN113912567B (zh) * 2020-07-08 2024-01-16 宜昌东阳光长江药业股份有限公司 吡喃葡萄糖基衍生物的制备方法及其中间体

Also Published As

Publication number Publication date
WO2020143653A1 (zh) 2020-07-16
CN113195510B (zh) 2022-12-23

Similar Documents

Publication Publication Date Title
CN113195510B (zh) 吡喃葡萄糖基衍生物的制备方法及其中间体
CN110582500B (zh) 双并环类核衣壳抑制剂和其作为药物用于治疗乙型肝炎的用途
JP2015129106A (ja) 光学的に純粋なベンジル‐４−クロロフェニル‐ｃ‐グルコシド誘導体
WO2008044762A1 (fr) Dérivé de spirocétal de thioglucose et utilisation de celui-ci comme agent thérapeutique pour le diabète
WO2001012588A1 (fr) Derives de salicylamide
JPS63145295A (ja) アントラサイクリン誘導体
JPH054985A (ja) 新規な化合物
JPH0261476B2 (zh)
US20080275241A1 (en) Polymorphic Forms of Dolasetron Base and Processes of Preparing Dolasetron Base, Its Polymorphic Forms and Salt Thereof
WO2009074020A9 (zh) α-氨基-N-取代酰胺化合物、包含该化合物的药物组合物及其用途
CN113912567A (zh) 吡喃葡萄糖基衍生物的制备方法及其中间体
CN109111490B (zh) 卤代新戊酰基吡喃葡萄糖及其用于sglt2抑制剂的制备方法
CN114075201B (zh) 一种西格列汀杂质的制备方法
TWI275588B (en) 1-trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives
WO2018087602A1 (en) Resolution of optically active diazaspiro[4.5]decane derivatives
JP2873417B2 (ja) フェニルアルカン酸エステル中間体の製造方法
JP3302647B2 (ja) フェニルアルカン酸エステルの塩酸塩、およびその製造方法
WO2024012568A1 (en) A key intermediate for preparing glucopyranosyl derivatives and preparation method thereof
CN110845486A (zh) 一种三氮唑醇类衍生物及其制备方法和应用
CN113330017B (zh) 一种SGLTs抑制剂的纯化方法及其应用
KR20070097535A (ko) 캄토테신의 입체선택적 방법 및 결정성 형태
WO1998023614A1 (fr) Nouveaux derives du phenanthridinium
HARADA et al. New Route to 1, 3, 3a, 8a-Tetrahydro-2H-benzofuro [2, 3-b] pyrrol-2-ones from Methyl α-Hydroxy-4H-1, 2-benzoxazine-4-acetates Obtained by Ring Transformation of 4-Aryl-2-isoxazoline 2-Oxides
TW202208378A (zh) 製備烷基7-胺基-5-甲基-[1,2,5]噁二唑并[3,4-b]吡啶羧酸酯之連續方法
Stirrat Toward the Synthesis of (–)-TAN-2483B Lactam Analogues

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right

Effective date of registration: 20210728

Address after: No.38 Binjiang Road, Yidu City, Yichang City, Hubei Province

Applicant after: YICHANG HEC CHANGJIANG PHARMACEUTICAL Co.,Ltd.

Address before: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Applicant before: SUNSHINE LAKE PHARMA Co.,Ltd.

TA01 Transfer of patent application right
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant